Pharmaceutical Technology on MSN
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...
Researchers identified distinct demographic, clinical, and serologic predictors of incident LVSD and cardiac recovery among patients with SSc.
FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...
It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...
MedPage Today on MSN
New Drug Approved for Hypertrophic Cardiomyopathy
"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...
Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...
Stocktwits on MSN
Cytokinetics wins first FDA approval for heart disease drug — why is Wall Street still cautious?
The drug is now expected to be available in the U.S. in the second half of January 2026. ・The prescribing information for the ...
The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...
Some people with heart failure need to take multiple medicines each day in order to keep their symptoms under control. Heart failure not only leads to issues in the heart but other organs in the body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback